Doraemi
2021-12-23
阅
诺瓦瓦克斯称其疫苗对奥密克戎等变异病毒广泛免疫
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":691414467,"tweetId":"691414467","gmtCreate":1640227230921,"gmtModify":1640227231014,"author":{"id":4095304727445630,"authorId":4095304727445630,"authorIdStr":"4095304727445630","name":"Doraemi","avatar":"https://static.tigerbbs.com/10c43206723220f2f2a9d8e027811291","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>阅</p></body></html>","htmlText":"<html><head></head><body><p>阅</p></body></html>","text":"阅","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691414467","repostId":2193113417,"repostType":4,"repost":{"id":"2193113417","pubTimestamp":1640216577,"share":"https://www.laohu8.com/m/news/2193113417?lang=&edition=full","pubTime":"2021-12-23 07:42","market":"hk","language":"zh","title":"诺瓦瓦克斯称其疫苗对奥密克戎等变异病毒广泛免疫","url":"https://stock-news.laohu8.com/highlight/detail?id=2193113417","media":"华尔街见闻","summary":"美东时间22日周三美股盘后,美国生物科技公司诺瓦瓦克斯公布,初步试验数据显示,针对奥密克戎及其他目前传播的变异毒株,该公司研发的新冠病毒疫苗可以产生广泛的免疫作用。诺瓦瓦克斯称,在完成共计两针的该司疫苗注射六个月后,若接种者再打第三针加强针,对上述新冠变异病毒的免疫效果还会加强。公布试验发现后,诺瓦瓦克斯股价盘后先跳水,跌幅一度超过8%,而后转涨,涨幅曾超过3%。","content":"<blockquote>\n 诺瓦瓦克斯还称,若再打第三针疫苗加强针,对这些新冠变异病毒的免疫效果会加强。其股价盘后先一度跌超8%,而后转涨,涨幅曾超过3%。\n</blockquote>\n<p>美东时间22日周三美股盘后,美国生物科技公司<a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a>公布,初步试验数据显示,针对奥密克戎及其他目前传播的变异毒株,该公司研发的新冠病毒疫苗可以产生广泛的免疫作用。</p>\n<p>诺瓦瓦克斯称,在完成共计两针的该司疫苗注射六个月后,若接种者再打第三针加强针,对上述新冠变异病毒的免疫效果还会加强。诺瓦瓦克斯的研发总裁Gregory M. Glenn在公告中表示,</p>\n<blockquote>\n “让我们感到鼓舞的是,对所有变异病毒的加强(免疫)反应是相对我们第三期临床试验中那些(病毒)相关的高疫苗效果而言的。这意味着,(我司新冠疫苗)NVX-CoV2373可以在当前对新变异病毒的抗疫过程中发挥重要作用。”\n</blockquote>\n<p>公告还称,鉴于新冠病毒在持续演化,研发一种奥密克戎的疫苗可能是必要的。诺瓦克克斯的奥密克戎疫苗将很快进入遵守生产质量管理规范的生产阶段,预计明年第一季度开始进行临床研究。</p>\n<p>公布试验发现后,诺瓦瓦克斯股价盘后先跳水,跌幅一度超过8%,而后转涨,涨幅曾超过3%。</p>\n<p><img src=\"https://static.tigerbbs.com/f3cf10bf95f8ce9a05ce0123b6643d02\" tg-width=\"1044\" tg-height=\"643\" referrerpolicy=\"no-referrer\"></p>","source":"sina_symbol","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺瓦瓦克斯称其疫苗对奥密克戎等变异病毒广泛免疫</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺瓦瓦克斯称其疫苗对奥密克戎等变异病毒广泛免疫\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 07:42 北京时间 <a href=https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/usstock/c/2021-12-23/doc-ikyakumx5795088.shtml><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>诺瓦瓦克斯还称,若再打第三针疫苗加强针,对这些新冠变异病毒的免疫效果会加强。其股价盘后先一度跌超8%,而后转涨,涨幅曾超过3%。\n\n美东时间22日周三美股盘后,美国生物科技公司诺瓦瓦克斯公布,初步试验数据显示,针对奥密克戎及其他目前传播的变异毒株,该公司研发的新冠病毒疫苗可以产生广泛的免疫作用。\n诺瓦瓦克斯称,在完成共计两针的该司疫苗注射六个月后,若接种者再打第三针加强针,对上述新冠变异病毒的免疫...</p>\n\n<a href=\"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/usstock/c/2021-12-23/doc-ikyakumx5795088.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6e474d690ea02c536f0fd4c03fc3ddef","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/usstock/c/2021-12-23/doc-ikyakumx5795088.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193113417","content_text":"诺瓦瓦克斯还称,若再打第三针疫苗加强针,对这些新冠变异病毒的免疫效果会加强。其股价盘后先一度跌超8%,而后转涨,涨幅曾超过3%。\n\n美东时间22日周三美股盘后,美国生物科技公司诺瓦瓦克斯公布,初步试验数据显示,针对奥密克戎及其他目前传播的变异毒株,该公司研发的新冠病毒疫苗可以产生广泛的免疫作用。\n诺瓦瓦克斯称,在完成共计两针的该司疫苗注射六个月后,若接种者再打第三针加强针,对上述新冠变异病毒的免疫效果还会加强。诺瓦瓦克斯的研发总裁Gregory M. Glenn在公告中表示,\n\n “让我们感到鼓舞的是,对所有变异病毒的加强(免疫)反应是相对我们第三期临床试验中那些(病毒)相关的高疫苗效果而言的。这意味着,(我司新冠疫苗)NVX-CoV2373可以在当前对新变异病毒的抗疫过程中发挥重要作用。”\n\n公告还称,鉴于新冠病毒在持续演化,研发一种奥密克戎的疫苗可能是必要的。诺瓦克克斯的奥密克戎疫苗将很快进入遵守生产质量管理规范的生产阶段,预计明年第一季度开始进行临床研究。\n公布试验发现后,诺瓦瓦克斯股价盘后先跳水,跌幅一度超过8%,而后转涨,涨幅曾超过3%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":338,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/691414467"}
精彩评论